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Diabetic peripheral neuropathy (DPN), a common and troublesome complication in patients with type 2 diabetes mellitus (T2DM), 
contributes to a higher risk of diabetic foot ulcer and lower limb amputation. These situations can negatively impact the quality 
of life of affected individuals. Despite its high prevalence and clinical importance, most diabetes mellitus patients not only do not 
recognize the presence of diabetic neuropathy, but also do not report their symptoms to physicians or other health care provid-
ers. Therefore, DPN is usually under diagnosed and undertreated. For early detection and appropriate intervention for DPN, a 
careful history, physical with neurologic examination, and prompt treatment are needed in T2DM patients.
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INTRODUCTION 
The prevalence of type 2 diabetes mellitus (T2DM) in Korea is 
estimated to be 7.3% (in those over 20 years of age), and it has 
increased about 5-fold over the past 30 years according to a re-
port of the Korea National Health and Nutrition Examination 
Survey (KNHNES III, 2005) [1,2]. The number of patients with 
T2DM is expected to increase dramatically from about 3.2 
million in 2011 (8.8% of the national population) to about 4.25 
million (11.1%) by 2030 [3]. This enormous increase in the 
number of T2DM patients will inevitably be accompanied by 
chronic diabetic microvascular or macrovascular complica-
tions. Among the diabetic complications, diabetic peripheral 
neuropathy (DPN) is the most prevalent and troublesome 
complication in patients with diabetes mellitus (DM). 
  Diabetic neuropathy (DN), which may be focal or diffuse, is 
diagnosed when diabetic patients complain of symptoms and/
or show signs of peripheral nerve dysfunction after the exclu-
sion of other etiologies [4,5]. Chronic sensorimotor DPN is 
the most common form of DN [6,7]. Peripheral neuropathic 
pain in diabetic patients is defined as pain arising as a direct 
consequence of abnormalities in the peripheral somatosenso-
ry system in people with diabetes [8]. The symptoms can be 
present as severe numbness, paresthesia, or hyperesthesia, how-
ever, DPN may be asymptomatic in about 50% of patients [9]. 
As the DPN progresses, the painful symptoms usually disap-
pear [10]. In addition, DPN is also associated with substantial 
morbidity, which includes not only a susceptibility to foot or 
ankle fractures and ischemic ulceration leading to lower-limb 
amputations, but also depression [11-13]. According to the 
Seattle Diabetic Foot Study, which included 749 diabetic pa-
tients, there were a number of findings that independently in-
crease the risk for DM foot ulcer, including certain foot defor-
mities, reduced foot arterial perfusion, and both sensory and 
autonomic neuropathy [14]. Diabetic patients with critical 
limb ischemia have high risks of lower limb amputation and 
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death [15].
  In addition to its influence on morbidity and mortality, 
painful symptoms in DPN have a significant detrimental im-
pact on quality of life as the condition limits daily activities 
and interferes with sleep [16-18]. Considering the health-re-
lated economic viewpoint, diabetic foot disease significantly 
increases the health care costs in patients with DM. According 
to a retrospective study that analyzed insurance costs in the 
United States, the cost of care for patients with a foot ulcer is 
5.4 times higher in the year after the first ulcer episode, but 2.8 
times higher in the second year compared with that of diabetic 
patients without foot ulcers [19]. Therefore, early detection 
and prompt intervention for DPN must be performed for pa-
tients with T2DM.
PREVALENCE OF DPN IN KOREAN PATIENTS 
WITH T2DM
The prevalence of DPN is generally estimated to be 10% to 
50% in patients with T2DM, and the incidence increases with 
age and duration of DM [17,18,20]. The reported prevalence 
of DN in Korea is variable, from 14.1% to 54.5% depending on 
the study population and the diagnostic method (Table 1) [21-
24]. In the Diabcare-Asia 1998 study, which included 230 DM 
centers from 12 countries (n=24,317), the frequencies of reti-
nopathy, microalbuminuria, and neuropathy were 21%, 39%, 
and 34%, respectively. The prevalence of those complications 
was significantly higher in those patients with higher hemoglo-
bin A1c (HbA1c) levels [22]. A nationwide survey performed 
in 2006 by the Committee of the Korean Diabetes Association 
on the Epidemiology of Diabetes Mellitus (n=5,652) showed 
that the prevalence of DPN defined by neurologic symptoms 
or nerve conduction velocity abnormalities was 44.7%. This 
prevalence was higher than the prevalence of microalbumin-
uria or retinopathy [23]. In a prospective observational study 
among 508 Korean T2DM patients, diabetic foot disease oc-
curred in 32 patients (6.3%), and the incidence of diabetic foot 
disease increased when peripheral neuropathy was present 
(odds ratio [OR], 2.949; 95% confidence interval [CI], 1.075 to 
8.090) [24].
  While chronic neuropathic pain is present in 13% to 26% of 
DM patients [25], it can be found not only in diabetic subjects, 
but also in impaired glucose tolerance (IGT) or impaired fast-
ing glucose individuals [26]. According to a community-based 
cross-sectional study from the United Kingdom, chronic DPN 
is common and often severe but frequently unreported and 
therefore inadequately treated [18]. Interestingly, they showed 
that 12.5% of patients had never reported their symptoms to 
their doctors, and 39.3% never received treatment [18]. 
  There are some studies about the relationships between 
DPN and other diabetic complications in Korean T2DM pa-
tients. Chung et al. [27] reported that the prevalence of cardio-
vascular disease (CVD) was higher in patients with DPN. In 
their multivariate analysis, DPN was independently associated 
with CVD (OR, 1.801; 95% CI, 1.009 to 3.214) in T2DM pa-
tients (n=1,041), with a 52.8% prevalence determined by neu-
rophysiologically diagnosing peripheral polyneuropathy based 
on electroneuromyographic findings. A close relationship be-
tween peripheral sensory neuropathy and peripheral vascular 
disease was also reported independent of glucose level and 
other microvascular complications, in particular, retinopathy 
in T2DM [20,28]. Other studies showed a relationship be-
tween DPN and arterial stiffness or insulin resistance [29,30]. 
The association between cardiovascular risk factors and devel-
opment of large-fiber nerve dysfunction, which was measured 
by vibration perception threshold, was reported in type 1 DM 
patients (n=1,407) in the EURODIAB Prospective Complica-
Table 1. Prevalence of diabetic neuropathy in patients with di-
abetes in Korea
Study year Diagnosis tool
Subjects 
No.
Preva-
lence, %
Kim et al. 1957-1977 NA 5,601 32.7
Han et al. 1963-1973 NA 1,332 22.9
Son et al. 1976 NA 3,076 28.9
Lee et al. 1976-1981 NA 779 14.1
Lee et al. 1981-1983 Symptoms, signs, NCV 300 54.5
Lee et al. 1982 Symptoms, signs, NCV 224 45.5
Hong et al. 1990 Symptoms, signs, NCV 837 48.9
Kim et al. 1993 Symptoms, signs, NCV 1,301 39.0
Park et al. 1994 Symptoms, signs, NCV 668 19.0
Kim et al. 1994 Symptoms, signs, NCV 235 37.5
Nam et al. 1999 Symptoms, signs, NCV 1,270 47.6
Park et al. 2003-2008 Symptoms, signs, NCV 508 13.9
Won et al. 2005 Symptoms, signs 875 53.9
Lim et al. 2006 Symptoms, signs, NCV 5,652 44.7
Won et al. 2010 Symptoms, signs 1,073 33.5
From Won JC, Ko KS. Korean Clin Diabetes 2010;11:177-83, with 
permission [21].
NA, not available; NCV, nerve conduction velocity.8
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tion Study [31]. These findings suggest the importance of DPN 
as a cardiovascular risk factor. 
PATHOGENESIS AND MECHANISM OF DPN
Hyperglycemia not only activates the sorbitol accumulation 
with a subsequent increase in cellular osmolarity, but it also 
shunts to the hexose pathway, producing oxidative stress and 
the formation of advanced glycation end products (Table 2) 
[11]. Damage to peripheral nerves results in hyperexcitability 
in the primary afferent nociceptors. This damage leads to hy-
perexcitability in central neurons and the generation of spon-
taneous impulses within the axons as well as the dorsal root 
ganglion of these peripheral nerves [32,33]. This mechanism is 
suggestive of an abnormality contributing to the pain in DPN. 
DIAGNOSIS OF DPN
The diagnosis of DPN usually depends on the subjective 
symptoms of neuropathy. Most of the clinical practice guide-
lines, including those from the Korean Diabetes Association, 
recommend that DPN screening should begin at the initial di-
agnosis of T2DM and should be performed at least annually 
thereafter [34-36]. The exclusion of non-diabetic causes of 
neuropathy, including alcoholism, vitamin B12 deficiency, en-
docrinopathies, vasculitides, heavy metal exposure, drug use, 
and malignancy, is important because these may account for 
10% of the cases of neuropathy in people with DM [37]. 
  Though the symptoms can exist without signs, the severity 
of painful symptoms can be reliably assessed by the visual ana-
logue scale or the numerical rating scale (0, no pain; 10, worst 
possible pain). This latter assessment is most widely used in 
neuropathic pain assessment [5]. In addition, validated scales 
and questionnaires such as the Neuropathic Pain Symptoms 
Inventory, the Brief Pain Inventory, and the Neuropathic Pain 
Questionnaires are widely used (Table 3) [5]. However, the 
nerve conduction study remains the most reliable, accurate, 
and sensitive method to evaluate peripheral nerve function, 
and it has been adopted as the gold standard. This approach is 
not only time-consuming, expensive, and insensitive for the 
detection of small-fiber neuropathy, but also it is impractical to 
perform in an outpatient clinic setting. However, the Semmes-
Weinstein monofilament (SWMF) test is simple to use as a 
screening tool to identify patients at risk for diabetic foot com-
plication in the primary care setting [38,39]. The inability to 
sense the 10 g force pressure is considered as insensate and an 
independent predictor for higher risk of foot ulceration [40]. 
Lee et al. [38] considered the SWMF test as a useful screening 
tool for DPN. The nerve conduction study (NCS) was used as 
a gold standard to compare the sensitivity and the specificity 
of the SWMF test. The results were considered as abnormal if 
the patient could not perceive the 5.07/10 g SWMF at more 
than four of ten sites (37 T2DM outpatients). The sensitivity 
and the specificity at two sites (the third and fifth metatarsal 
head sites) were 93.1% and 100%, the same as at the ten sites. 
It is likely that the two-site SWMF test is a useful screening test 
for DPN as is the ten-site test. In a study of 126 diabetic pa-
tients, 41% complained of DPN symptoms, and SWMF and 
vibration perception were more impaired in patients with sub-
jective sensory symptoms [39]. In 82 diabetic patients, the 
medial plantar sensory NCS provided a more sensitive diag-
nosis of DPN, even in patients with normal range measure-
ments in the sural nerve [41]. The medial plantar sensory 
nerve action potential was abnormal in 46.7% of the symp-
tomatic and 14.3% of the asymptomatic diabetic patients with 
normal routine NCS in this study [41]. The medial plantar 
sensory NCS may be helpful in the diagnosis of subclinical 
DPN in the asymptomatic diabetic patient. Compared to the 
Table 2. Pathogenesis of diabetic peripheral neuropathy
Hyperglycemia
Increased ROS generation
Sorbitol accumulation
Osmolarity-related nerve damage
Hexosamine pathway
Modify specific transcription factors
Formation of AGEs
Decreased biologic function of proteins
Inhibit neuronal activity
Initiate Inflammatory signaling cascade
Dyslipidemia
FFA-induced lipotoxicity
ROS and mitochondria-activated injury
Inflammatory cytokine
Oxidized and glycated LDLs
Insulin resistance
Inflammation and ER stress in neuron
ROS, reactive oxidative stress; AGE, advanced glycation end product; 
FFA, free fatty acid; LDL, low density lipoprotein; ER stress, endo-
plasmic reticulum stress.9
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Table 3. Diagnosis of diabetic peripheral neuropathy
Diagnostic method
Visual examination Skin changes, ulceration or ulcer
Neuropathic pain  
assessment
Michigan Neuropathy Screening Instrument 
(MNSI)
Neuropathy Disability Score (NDS)
Brief Pain Inventory (BPI)
Neuropathic Pain Questionnaire (NPQ)
Neuropathic Pain Symptom Inventory (NPSI)
Peripheral motor 
neuropathy
Callus formation, muscle atrophy, planus feet 
or deformity 
Muscle strength
Deep tendon reflex at Achilles tendon
Sensory function Pinprick test (Apply proximal to great toenail)
Temperature perception (Tiptherm rod on 
dorsum of foot)
Vibration perception (128 Hz Tuning fork at 
great toe apex)
Neurothesiometer or Biothesiometer at tip of 
hallux, measured in volts
Touch sensation 10 g monofilament (SW 
monofilament)
Electrophysiologic 
study
Nerve conduction study
Skin biopsy Quantification of intra-epidermal nerve fiber
Skin blood flow 
measurement
Measurement microvascular perfusion
QOL questionnaire 
Norfolk QOL  
questionnaire 
Specific symptoms and impact of large, small 
and autonomic nerve-fiber functions
Neuro QOL Patients’ perceptions of the impact of neurop-
athy and foot ulcers
PN-QOL-97 Health-related quality of life measure for Pe-
ripheral neuropathy
New tests
Large fiber  
function test 
Steel ball-bearing 
Tactile circumferential discriminator
Autonomic nerve conduction study
Small fiber  
function test
NeuroQuick 
Neuropad
SW monofilament, Semmes-Weinstein monofilament (SWMF); QOL, 
quality of life.
single test, the combinations of tests have a greater than 87% 
sensitivity in detecting DPN [4]. 
TREATMENT OF DPN 
The aims of DPN treatment are to decrease the painful symp-
toms, to treat the specific pathogenic mechanism, and to pre-
vent progression or subsequent complications. Treatment of 
the pain of DPN is mainly symptomatic management [42]. 
Most of all, strict diabetic control and correction of metabolic 
risk factors should be initiated. The lifestyle intervention that 
improves glycemic control and decreases blood pressure with 
lipid profiles improves both the painful neuropathic symp-
toms and the intra-epidermal nerve fiber density. These find-
ings suggest that early diagnosis and prompt intervention may 
be of significant clinical benefit [32].
  For pharmacological treatment, first line therapy consists of 
tricyclic antidepressants (TCA), duloxetine, pregabalin or 
oxycodone (Table 4) [36]. If the pain is not controlled with 
first-line therapy, second-line therapy or combination therapy 
can be used, for which the potential side effects and possible 
drug interactions must be considered. Topical treatment with 
a 5% lidocaine plaster or capsaicin is also considered.
  Randomized controlled trials have been performed for the 
treatment of DPN in Korean patients with T2DM using alpha-
lipoic acid, pregabalin, or tramadol/acetaminophen combina-
tion treatment. The neuropathic symptom score, assessed by 
the Total Symptom Score, was improved after intravenous al-
pha-lipoic acid treatment at a dose of 600 mg/day for 14 days 
in 19 T2DM patients compared to 13 control subjects (P<0.05) 
[43]. Open-label study with oral thioctic acid 600 mg once 
daily for 8 weeks (n=61) also improved DPN symptoms with-
out serious adverse effects in Korean diabetic patients [44]. In 
an open, randomized, comparative study conducted in 163 
T2DM subjects with DPN, tramadol/acetaminophen (Ul-
tracet
@) treatment (n=79) for 6 weeks was as effective as gaba-
pentin (n=84) for the decrease of pain intensity, an increase in 
the quality of life, an increase in mood, and a decrease in sleep 
disturbance in the treatment of painful DN [45]. Ten weeks of 
pregabalin treatment for patients with neuropathic pain (DPN 
[type 1 or 2 diabetes, n=18], postherpetic neuralgia [n=146], 
or posttraumatic neuropathic pain [n=76]; n=162 pregabalin, 
n=78 placebo) showed a significant reduction in the Daily 
Pain Rating Scale score with improvement in anxiety and a 
decrease in sleep disturbance [46]. Despite the improvement 
in treatment modalities for chronic pain in recent years, pa-
tients with DPN still continue to be inadequately treated [47]. 10
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CONCLUSION
The dramatic increase in the prevalence of T2DM with its acute 
or chronic complications are a major health concern in Korea. 
Screening of high risk individuals, early detection, and proper 
management of DPN in patients with T2DM is urgently need-
ed. Careful foot examination, active application of outpatient 
screening tools including the assessment of pedal pulses, and 
an organized diabetic foot-care program are needed. 
  Despite the improvement in treatment modalities for 
chronic pain in recent years, patients with DPN continue to be 
inadequately treated. Therefore, active pharmacologic treat-
ment should be considered to relieve neuropathic pain and 
improve the quality of life in patients with T2DM.
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